Lexicon Pharma (LXRX) Tops Q3 EPS by 3c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.22 +2.78%
EPS Growth %: -600.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -600.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $14.1 million versus the consensus estimate of $4.65 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
- Micron Technology (MU) PT Raised to $1,280 at Baird
- Barclays Upgrades Keurig Dr Pepper (KDP) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
